Jaguar Health to Showcase Gelclair for Oral Mucositis at ASCO Annual Meeting

Jaguar Health, Inc. (NASDAQ:JAGX) announced plans to debut their cancer supportive care product, Gelclair, at the American Society of Clinical Oncology (ASCO) Annual Meeting. This event, scheduled from May 31 to June 4, spotlights the FDA-approved prescription gel designed to alleviate oral mucositis pain.

Oral mucositis, a significant cancer treatment side effect, afflicts up to 40% of chemotherapy patients and 90% of those receiving head and neck cancer treatments. Jaguar's CEO, Lisa Conte, emphasized Gelclair's non-numbing, protective properties that soothe oral lesions without stinging.

The company also anticipates imminent results from a phase 3 trial for crofelemer, aimed at preventing cancer therapy-related diarrhea. Jaguar's presence at ASCO underscores the company's commitment to enhancing cancer patient care through innovative supportive treatments.